KU-32, a Novel Drug for Diabetic Neuropathy, Is Safe for Human Islets and Improves In Vitro Insulin Secretion and Viability
Figure 8
Insulin staining intensity per cell was higher with KU-32 treatment. Representative examples are shown of insulin immunohistochemistry for islets from vehicle-treated and KU-32 administered mice. (b) Insulin staining intensity values (brown) were background-subtracted (blue) and calculated as pixel intensity. KU-32 induced a significant increase in insulin staining. (*indicates , β cells from 7 vehicle-treated mice and 682 β cells from 5 KU-32-treated mice).
